coffee in duderstadt - out of the pan and into the fire "dendritric cell vaccine"

https://docs.google.com/file/d/1odbnNoKKsNYlsI17dkXBZ6s3bgSEPt4-iPkpqemeP00ZVUpZQJ1oqJpZQnuZ/edit

written by Thomas Neßelhut1, Dagmar Marx1, Jan Neßelhut1 and Fred Fändrich2
1Institute for Tumortherapy, Duderstadt
2Clinic for Applied Cellular Medicine, University of Kiel
Germany

these amazing doctors and researchers are saving lives without chemo, they are not sharks, they are legends and I am blessed to be here when all my sydney oncologists wereing offering palliative chemo and a quick longer term visit to lucifer! to much loving and living to do!

starting the above therapy tomorrow, but the colorectal version.

will this save my but ?

only one way to find out! i just left hallwangen clinic after 2 months and a small $100Kusd bill, now i am at duderstadt for 4 months of therapy. I will be back scuba diving in under 3 weeks, not a bad effort for 46 year old which had some mets to the liver, lung and peritoneal cavity. just about to redo the ct and pet, maybe sydney or germany. i feel fine and will have as much fun and excitement as treatment permits.

hugs,
pete

ps the science is compelling, thank you nwnm aka tony. your suggestions months ago were the equivalent to foreplay, all those months ago how ironic i am using this now. when you are a trail blazer you get shot by some and loved by others. one day I pray we will all realise "we can have our cake and eat it" please read and push your oncologists hard to expand their clinical awareness. they have to stop looking at themselves in the mirror each morning and think of you and realise the germans almost won the war. maybe they will win the war on cancer. thats my bet! thats where my life and money is going. you bet with your decisions, bet well my friends and have fun. I am! The roulette wheel is still spinning and I am still breathing. amen and thank you to all my friends.

pps my blog weeks ago about nobel prize winning science being implemented here.
http://petertrayhurn.blogspot.de/2012/11/todays-research-ginseng-nobel-prize.html

ppps this is the juicy part of the paper I have studied, its going to save my life with low or no chemo! thats my prayer.

promote antigen-specific recognition and avidity of potential anti-tumor effector cells, the
biology of antigens expressed by malignant glioma cells must be taken into consideration
while designing protocols for programming autologous dendritic cells and defining the
appropriate patient. For example, Prins and coworkers could recently shown that the gene
expression profile of the individual glioma can identify a subgroup of patients, that may be
more responsive to dendritic cell based immunotherapy (Prins et al., 2011). In this context
the combination with NDV seems to be a promising tool to modify tumor cells in vitro as
well as in vivo to a more immunogenic phenotype resulting in better immune recognition as
well as in better immune response.
The encouraging results of phase I/II trials have to be confirmed in phase III studies with
special emphasis on the maturation protocols for improvement of TH1-polarisation of
dendritic cells, which so far are still a matter of controversial discussion. Moreover, the
optimal antigen source, cell number of injected dendritic cells, frequency of vaccinations as
well as the right time point for vaccination are still not fully defined. Future studies should
also involve an immune monitoring of vaccinated patients. Immune monitoring methods
can include quantification of CD8+ and CD4+ T cells generated in response to the antigen or
measurement of the functional status of T cells analyzed by cytokine production. However,
it has to be taken into account that in vitro measurement of T cell responses do not always
correlate with clinical outcome (Carpentier & Meng, 2006). Thus, the best immunological
monitoring strategy is still intensively debated.
Finally, clinical trials for the evaluation of immune therapeutical approaches have to be
designed in a different way as for chemotherapeutical drugs. In this context the overall
survival rather than the reduction of tumor burden is probably the best primary endpoint.
Based on such a study design ProvengeTM, an immunological treatment based on antigen
presenting cells, received the FDA approval for treatment of hormone refractory prostate
cancer in spring 2010.

pppps http://petertrayhurn.blogspot.de/2012/12/my-life-in-his-hands.html
picture of my actual colorectal targetted personal vaccine.